Publications
| Hansen M, Hjortø GM, Met O, Jakobsen MH, Svane IM, Larsen NB. |
| Cell culture plastics with immobilized interleukin-4 for monocyte differentiation. J Biomed Mater Res A. 2011 Feb; 96(2): 372-83. Pubmed | View abstract |
| Hansen M, Hjortø GM, Met O, Jakobsen MH, Svane IM, Larsen NB. |
| Cell culture plastics with immobilized interleukin-4 for monocyte differentiation. J Biomed Mater Res A. 2010 Dec 8; [Epub ahead of print] Pubmed | View abstract |
| Sørensen RB, Hadrup SR, Svane IM, Hjortsø MC, Thor Straten P, Andersen MH. |
| Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood. 2010 Nov 15; [Epub ahead of print] Pubmed | View abstract |
| Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, Svane IM. |
| Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol. 2010 Dec; 72(6): 540-7. Pubmed | View abstract |
| Andersen RS, Sørensen RB, Ritter C, Svane IM, Becker JC, Thor Straten P, Andersen MH. |
| Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. Cancer Immunol Immunother. 2010 Oct 28; [Epub ahead of print] Pubmed | View abstract |
| Schmidt H, Brown J, Mouritzen U, Selby P, Fode K, Svane IM, Cook GP, Mollerup DH, Geertsen PF. |
| Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. Clin Cancer Res. 2010 Nov; 16(21): 5312-9. Pubmed | View abstract |
| Andersen MH, Junker N, Ellebaek E, Svane IM, Thor Straten P. |
| Therapeutic cancer vaccines in combination with conventional therapy. J Biomed Biotechnol. 2010 ; 2010(): 237623. Pubmed | View abstract |
| Søndergaard H, Galsgaard ED, Bartholomaeussen M, Straten PT, Odum N, Skak K. |
| Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes. J Immunother. 2010 Apr; 33(3): 236-49. Pubmed | View abstract |
| Trepiakas R, Berntsen A, Hadrup SR, Bjørn J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A, Lorentzen T, Johansen JS, Svane IM. |
| Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy. 2010 Oct; 12(6): 721-34. Pubmed | View abstract |
| Berntsen A, Brimnes MK, thor Straten P, Svane IM. |
| Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother. 2010 May; 33(4): 425-34. Pubmed | View abstract |
| Met O, Balslev E, Flyger H, Svane IM. |
| High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat. 2011 Jan; 125(2): 395-406. Pubmed | View abstract |
| Tsakiri A, Tsiantoulas D, Frederiksen J, Svane IM. |
| Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatin. Exp Neurol. 2010 Feb; 221(2): 320-8. Pubmed | View abstract |
| Sørensen RB, thor Straten P, Andersen MH. |
| Comment on "Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression". J Immunol. 2009 Nov; 183(10): 6040. Pubmed | View abstract |
| Soleimani A, Berntsen A, Svane IM, Pedersen AE. |
| Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand J Immunol. 2009 Nov; 70(5): 481-9. Pubmed | View abstract |
| Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, thor Straten P, Andersen MH. |
| The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One. Pubmed | View abstract |
| Andersen MH, Sørensen RB, Brimnes MK, Svane IM, Becker JC, thor Straten P. |
| Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest. 2009 Aug; 119(8): 2245-56. Pubmed | View abstract |
| Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, Castermans E, Thor Straten P, Blank C, Haanen JB, Heemskerk MH, Schumacher TN. |
| Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods. 2009 Jul; 6(7): 520-6. Pubmed | View abstract |
| Køllgaard T, Duval L, Schmidt H, Kaltoft K, Seremet T, Andersen MH, Maase H, Straten P, Hadrup SR. |
| Longitudinal immune monitoring of patients receiving intratumoral injection of a MART-1 T-cell receptor-transduced cell line (C-Cure 709). Cytotherapy. 2009 ; 11(5): 631-41. Pubmed | View abstract |
| Kloverpris H, Karlsson I, Bonde J, Thorn M, Vinner L, Pedersen AE, Hentze JL, Andresen BS, Svane IM, Gerstoft J, Kronborg G, Fomsgaard A. |
| Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS. 2009 Jul; 23(11): 1329-40. Pubmed | View abstract |
| Wenandy L, Kollgaard T, Letsch A, Andersen RS, Stather D, Seremet T, Svane IM, Vindeløv L, Andersen MH, thor Straten P. |
| The 1170 A-P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag). Leukemia. 2009 Oct; 23(10): 1926-9. Pubmed | View abstract |
| Trepiakas R, Pedersen AE, Met O, Svane IM. |
| Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine. 2009 Apr; 27(16): 2213-9. Pubmed | View abstract |
| Hofmann UB, Voigt H, Andersen MH, Straten PT, Becker JC, Eggert AO. |
| Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes. Eur J Immunol. 2009 May; 39(5): 1419-24. Pubmed | View abstract |
| Sørensen RB, Andersen RS, Svane IM, Engell-Noerregaard L, Hadrup SR, Balslev E, Andersen MH, thor Straten P. |
| CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin Cancer Res. 2009 Mar; 15(5): 1543-9. Pubmed | View abstract |
| Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G. |
| Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol Immunother. 2009 Oct; 58(10): 1609-26. Pubmed | View abstract |
| Baek Sørensen R, Faurschou M, Troelsen L, Schrama D, Jacobsen S, Becker JC, Thor Straten P, Andersen MH. |
| Melanoma inhibitor of apoptosis protein (ML-IAP) specific cytotoxic T lymphocytes cross-react with an epitope from the auto-antigen SS56. J Invest Dermatol. 2009 Aug; 129(8): 1992-9. Pubmed | View abstract |
| Hofmeister-Mueller V, Vetter-Kauczok CS, Ullrich R, Meder K, Lukanidin E, Broecker EB, Straten P, Andersen MH, Schrama D, Becker JC. |
| Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients. Cancer Immunol Immunother. 2009 Aug; 58(8): 1265-73. Pubmed | View abstract |
| Sørensen RB, Svane IM, Straten PT, Andersen MH. |
| A survivin specific T-cell clone from a breast cancer patient display universal tumor cell lysis. Cancer Biol Ther. 2008 Dec; 7(12): 1885-7. Pubmed | View abstract |
| Sørensen RB, Junker N, Kirkin A, Voigt H, Svane IM, Becker JC, thor Straten P, Andersen MH. |
| The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines. Cancer Immunol Immunother. 2009 May; 58(5): 665-75. Pubmed | View abstract |
| Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Claesson MH, Lorentzen T, Johansen JS, Svane IM. |
| Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother. 2008 Oct; 31(8): 771-80. Pubmed | View abstract |
| Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. |
| Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009 Jan; 58(1): 1-14. Pubmed | View abstract |
| Svane IM, Pedersen AE, Nikolajsen K, Zocca MB. |
| Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Vaccine. 2008 Aug; 26(36): 4716-24. Pubmed | View abstract |
| Met O, Eriksen J, Svane IM. |
| Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential. Mol Biotechnol. 2008 Oct; 40(2): 151-60. Pubmed | View abstract |
| Kvistborg P, Hadrup SR, Svane IM, Andersen MH, Straten PT. |
| Characterization of a single peptide derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients. Hum Immunol. ; 69(4-5): 266-72. Pubmed | View abstract |
| Trepiakas R, Pedersen AE, Met O, Hansen MH, Berntsen A, Svane IM. |
| Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine. 2008 Jun; 26(23): 2824-32. Pubmed | View abstract |
| Wenandy L, Sørensen RB, Svane IM, Thor Straten P, Andersen MH. |
| RhoC a new target for therapeutic vaccination against metastatic cancer. Cancer Immunol Immunother. 2008 Dec; 57(12): 1871-8. Pubmed | View abstract |
| Kollgaard T, Hadrup SR, Petersen SL, Masmas TN, Andersen MH, Spierings E, Vindeløv L, Straten PT. |
| Natural T-cell responses against minor histocompatibility antigen (mHag) HY following HLA-matched hematopoietic cell transplantation: what are the requirements for a 'good' mHag? Leukemia. 2008 Oct; 22(10): 1948-51. Pubmed | View abstract |
| Andersen MH, Sørensen RB, Schrama D, Svane IM, Becker JC, Thor Straten P. |
| Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother. 2008 Nov; 57(11): 1735-43. Pubmed | View abstract |
| Wenandy L, Sørensen RB, Sengeløv L, Svane IM, thor Straten P, Andersen MH. |
| The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res. 2008 Jan; 14(1): 4-7. Pubmed | View abstract |
| Andersen MH, Svane IM, Becker JC, Straten PT. |
| The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 2007 Oct; 13(20): 5991-4. Pubmed | View abstract |
| Svane IM, Nikolajsen K, Johnsen HE. |
| Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination. Scand J Immunol. 2007 Oct; 66(4): 465-75. Pubmed | View abstract |
| Andersen RS, Wenandy L, Sørensen RB, thor Straten P, Andersen MH. |
| Mcl-1 and anticancer vaccination: identification of an HLA-A2-restricted epitope. Leukemia. 2008 Mar; 22(3): 668-9. Pubmed | View abstract |
| Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanović S, Wölfel T, van der Burg SH. |
| The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother. 2008 Mar; 57(3): 289-302. Pubmed | View abstract |
| Schrama D, Voigt H, Eggert AO, Xiang R, Zhou H, Schumacher TN, Andersen MH, thor Straten P, Reisfeld RA, Becker JC. |
| Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue. Cancer Immunol Immunother. 2008 Jan; 57(1): 85-95. Pubmed | View abstract |
| Mathieu MG, Knights AJ, Pawelec G, Riley CL, Wernet D, Lemonnier FA, Straten PT, Mueller L, Rees RC, McArdle SE. |
| HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. Cancer Immunol Immunother. 2007 Dec; 56(12): 1885-95. Pubmed | View abstract |
| Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, Ottesen S, Balslev E, Gaarsdal E, Nikolajsen K, Claesson MH. |
| Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother. 2007 Sep; 56(9): 1485-99. Pubmed | View abstract |
| Dorn T, Kuhn U, Bungartz G, Stiller S, Bauer M, Ellwart J, Peters T, Scharffetter-Kochanek K, Semmrich M, Laschinger M, Holzmann B, Klinkert WE, Straten PT, Køllgaard T, Sixt M, Brakebusch C. |
| RhoH is important for positive thymocyte selection and T-cell receptor signaling. Blood. 2007 Mar; 109(6): 2346-55. Pubmed | View abstract |
| Andersen MH, Soerensen RB, Becker JC, thor Straten P. |
| HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer. J Transl Med. Pubmed | View abstract |
| Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G. |
| T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother. 2007 May; 56(5): 659-75. Pubmed | View abstract |
| Sørensen RB, Hadrup SR, Køllgaard T, Svane IM, thor Straten P, Andersen MH. |
| Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunol Immunother. 2007 Apr; 56(4): 527-33. Pubmed | View abstract |
| Friedrichs B, Siegel S, Andersen MH, Schmitz N, Zeis M. |
| Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies. Leuk Lymphoma. 2006 Jun; 47(6): 978-85. Pubmed | View abstract |
| Sørensen RB, Nielsen OJ, Thor Straten P, Andersen MH. |
| Functional capacity of Mcl-1-specific cytotoxic T-cells. Leukemia. 2006 Aug; 20(8): 1457-8. Pubmed | View abstract |
| Berntsen A, Geertsen PF, Svane IM. |
| Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol. 2006 Jul; 50(1): 34-43. Pubmed | View abstract |
| Svane IM, Berntsen A, Trepiakas R, Pedersen AE. |
| [Dendrite cell-based cancer vaccines--clinical application]. Ugeskr Laeger. 2006 Apr; 168(14): 1415-20. Danish. Pubmed | View abstract |
| Hadrup SR, Gehl J, Sørensen RB, Geertsen PF, Straten PT, Andersen MH. |
| Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission. Cancer Biol Ther. 2006 May; 5(5): 480-2. Pubmed | View abstract |
| Gad M, Lundsgaard D, Kjellev S, Kristensen NN, Seremet T, Straten PT, Claesson MH. |
| Reactivity of naive CD4+CD25- T cells against gut microflora in healthy mice. Int Immunol. 2006 May; 18(5): 817-25. Pubmed | View abstract |
| Hadrup SR, Braendstrup O, Jacobsen GK, Mortensen S, Pedersen LØ, Seremet T, Andersen MH, Becker JC, Straten PT. |
| Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. Int J Cancer. 2006 Aug; 119(4): 831-8. Pubmed | View abstract |
| Brimnes MK, Svane IM, Johnsen HE. |
| Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol. 2006 Apr; 144(1): 76-84. Pubmed | View abstract |
| Fensterle J, Trefzer U, Berger T, Andersen MH, Ugurel S, Becker JC. |
| HLA-B8 association with late-stage melanoma--an immunological lesson? BMC Med. Pubmed | View abstract |
| Svane IM, Nikolajsen K, Walter MR, Buus S, Gad M, Claesson MH, Pedersen AE. |
| Characterization of monocyte-derived dendritic cells maturated with IFN-alpha. Scand J Immunol. 2006 Mar; 63(3): 217-22. Pubmed | View abstract |
| Hadrup SR, Strindhall J, Køllgaard T, Seremet T, Johansson B, Pawelec G, thor Straten P, Wikby A. |
| Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol. 2006 Feb; 176(4): 2645-53. Pubmed | View abstract |
| Andersen MH, Schrama D, Thor Straten P, Becker JC. |
| Cytotoxic T cells. J Invest Dermatol. 2006 Jan; 126(1): 32-41. Pubmed | View abstract |
| Schrama D, Terheyden P, Otto K, Kämmerer U, Bröcker EB, Lühder F, Cosman D, Andersen MH, Becker JC. |
| Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells. Eur J Immunol. 2006 Jan; 36(1): 65-72. Pubmed | View abstract |
| Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N. |
| Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005 Dec; 65(23): 11136-45. Pubmed | View abstract |
| Kollgaard T, Petersen SL, Hadrup SR, Masmas TN, Seremet T, Andersen MH, Madsen HO, Vindeløv L, thor Straten P. |
| Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation. Leukemia. 2005 Dec; 19(12): 2273-80. Pubmed | View abstract |
| Andersen MH, Reker S, Kvistborg P, Becker JC, thor Straten P. |
| Spontaneous immunity against Bcl-xL in cancer patients. J Immunol. 2005 Aug; 175(4): 2709-14. Pubmed | View abstract |
| Andersen MH, Gehl J, Reker S, Geertsen P, Becker JC, thor Stratem P. |
| Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: the good, the bad, or the evil? J Clin Oncol. 2005 Aug; 23(22): 5265-7; author reply 5267-8. Pubmed | View abstract |
| Straten P, Dahl C, Schrama D, Pedersen LØ, Andersen MH, Seremet T, Bröcker EB, Guldberg P, Becker JC. |
| Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes. Cancer Immunol Immunother. 2006 May; 55(5): 495-502. Pubmed | View abstract |
| Andersen MH, Becker JC, Straten P. |
| Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov. 2005 May; 4(5): 399-409. Pubmed | View abstract |
| Andersen MH, Kvistborg P, Becker JC, Thor Straten P. |
| Identification of an HLA-A1 restricted CTL epitope from Mcl-1. Leukemia. 2005 Jun; 19(6): 1084-5. Pubmed | View abstract |
| Becker JC, thor Straten P, Andersen MH. |
| The paradoxical association between Bcl-2 expression and prognosis: does the immune system make the difference? Cancer Res. 2005 Apr; 65(7): 2983. Pubmed | View abstract |
| Pedersen AE, Thorn M, Gad M, Walter MR, Johnsen HE, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH, Svane IM. |
| Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand J Immunol. 2005 Feb; 61(2): 147-56. Pubmed | View abstract |
| Celis JE, Moreira JM, Gromova I, Cabezon T, Ralfkiaer U, Guldberg P, Straten PT, Mouridsen H, Friis E, Holm D, Rank F, Gromov P. |
| Towards discovery-driven translational research in breast cancer. FEBS J. 2005 Jan; 272(1): 2-15. Pubmed | View abstract |
| Andersen MH, Becker JC, Thor Straten P. |
| The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients. Leukemia. 2005 Mar; 19(3): 484-5. Pubmed | View abstract |
| Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LØ, Rath JC, Böck M, Bröcker EB, Straten PT, Kämpgen E, Becker JC. |
| Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine. 2005 Jan; 23(7): 884-9. Pubmed | View abstract |
| Meier A, Reker S, Svane IM, Holten-Andersen L, Becker JC, Søndergaard I, Andersen MH, Thor Straten P. |
| Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. Cancer Immunol Immunother. 2005 Mar; 54(3): 219-28. Pubmed | View abstract |
| Nielsen DL, Svane IM. |
| [High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy in primary breast cancer. An analysis of a systematic Cochrane review]. Ugeskr Laeger. 2004 Nov; 166(46): 4148-50. Danish. Pubmed | View abstract |
| Nielsen DL, Svane IM. |
| [High dose chemotherapy versus conventional chemotherapy in metastasing breast cancer. An analysis of a systematic Cochrane review]. Ugeskr Laeger. 2004 Nov; 166(46): 4145-7. Danish. Pubmed | View abstract |
| Eggert AO, Andersen MH, Voigt H, Schrama D, Kämpgen E, Straten PT, Becker JC. |
| Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes. Eur J Immunol. 2004 Nov; 34(11): 3285-90. Pubmed | View abstract |
| Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, Becker JC, Straten PT. |
| Immunogenicity of Bcl-2 in patients with cancer. Blood. 2005 Jan; 105(2): 728-34. Pubmed | View abstract |
| Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P, Berger TG, Schadendorf D, Trefzer U, Bröcker EB, Straten P, Rapp UR, Becker JC. |
| Immunogenicity of constitutively active V599EBRaf. Cancer Res. 2004 Aug; 64(15): 5456-60. Pubmed | View abstract |
| Do TH, Johnsen HE, Kjaersgaard E, Taaning E, Svane IM. |
| Impaired circulating myeloid DCs from myeloma patients. Cytotherapy. 2004 ; 6(3): 196-203. Pubmed | View abstract |
| Berger TG, Haendle I, Schrama D, Lüftl M, Bauer N, Pedersen LØ, Schuler-Thurner B, Hohenberger W, Straten Pt P, Schuler G, Becker JC. |
| Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells. Int J Cancer. 2004 Aug; 111(2): 229-37. Pubmed | View abstract |
| Andersen MH, Becker JC, Straten P. |
| Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP. J Invest Dermatol. 2004 May; 122(5): 1336-7. Pubmed | View abstract |
| Schrama D, Xiang R, Eggert AO, Andersen MH, Pedersen Ls LØ, Kämpgen E, Schumacher TN, Reisfeld RR, Becker JC. |
| Shift from systemic to site-specific memory by tumor-targeted IL-2. J Immunol. 2004 May; 172(10): 5843-50. Pubmed | View abstract |
| Thor Straten P, Schrama D, Andersen MH, Becker JC. |
| T-cell clonotypes in cancer. J Transl Med. Pubmed | View abstract |
| Andersen MH, Reker S, Becker JC, thor Straten P. |
| The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J Invest Dermatol. 2004 Feb; 122(2): 392-9. Pubmed | View abstract |
| Andersen MH, Gehl J, Reker S, Pedersen LØ, Becker JC, Geertsen P, thor Straten P. |
| Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol. 2003 Dec; 13(6): 449-59. Pubmed | View abstract |
| Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH. |
| Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul; 53(7): 633-41. Pubmed | View abstract |
| Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH. |
| Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther. 2004 Feb; 3(2): 173-9. Pubmed | View abstract |
| Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. |
| HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer. 2004 Mar; 108(6): 937-41. Pubmed | View abstract |
| Svane IM, Homburg KM, Kamby C, Nielsen DL, Roer O, Sliffsgaard D, Johnsen HE, Hansen SW. |
| Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study. Acta Oncol. 2002 ; 41(7-8): 675-83. Pubmed | View abstract |
| Terheyden P, Schrama D, Pedersen LØ, Andersen MH, Kämpgen E, thor Straten P, Becker JC. |
| Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression. Scand J Immunol. 2003 Nov; 58(5): 566-71. Pubmed | View abstract |
| Svane IM, Soot ML, Buus S, Johnsen HE. |
| Clinical application of dendritic cells in cancer vaccination therapy. APMIS. ; 111(7-8): 818-34. Pubmed | View abstract |
| Schrama D, Eggert AA, Bröcker EB, Pedersen LO, thor Straten P, Becker JC. |
| Immunological consequences of the sentinel lymph-node biopsy--lessons from a melanoma patient. Lancet Oncol. 2003 Jul; 4(7): 446-7. Pubmed | View abstract |
| Celis JE, Gromov P, Gromova I, Moreira JM, Cabezón T, Ambartsumian N, Grigorian M, Lukanidin E, Thor Straten P, Guldberg P, Bartkova J, Bartek J, Lukas J, Lukas C, Lykkesfeldt A, Jäättelä M, Roepstorff P, Bolund L, Ørntoft T, Brünner N, Overgaard J, Sandelin K, Blichert-Toft M, Mouridsen H, Rank FE. |
| Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol Cell Proteomics. 2003 Jun; 2(6): 369-77. Pubmed | View abstract |
| Svane IM, Engel AM. |
| Immune selection in murine tumors. Ph.d thesis. APMIS Suppl. 2003 ; (106): 1-46. Pubmed | View abstract |
| Schrama D, Pedersen LØ, Keikavoussi P, Andersen MH, Straten Pt P, Bröcker EB, Kämpgen E, Becker JC. |
| Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells. J Invest Dermatol. 2002 Dec; 119(6): 1443-8. Pubmed | View abstract |
| Schrama D, Fuchs E, Bröcker EB, Thor Straten P, Becker JC. |
| Identical T-cell receptor transcripts in multiple melanoma metastases. Cancer Res. 2002 Oct; 62(20): 5664-7. Pubmed | View abstract |
| Svane IM, Nikolajsen K, Hansen SW, Kamby C, Nielsen DL, Johnsen HE. |
| Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Application of new flow cytometric method. Bone Marrow Transplant. 2002 Apr; 29(8): 659-66. Pubmed | View abstract |
| Andersen MH, Schmidt H, Gehl J, von der Maase H, Straten P. |
| [Immunotherapy of cancer]. Ugeskr Laeger. 2002 Jun; 164(23): 3008-16. Danish. Pubmed | View abstract |
| Andersen MH, thor SP. |
| Survivin--a universal tumor antigen. Histol Histopathol. 2002 Apr; 17(2): 669-75. Pubmed | View abstract |
| Vetter CS, Groh V, thor Straten P, Spies T, Bröcker EB, Becker JC. |
| Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol. 2002 Apr; 118(4): 600-5. Pubmed | View abstract |
| Pedersen LØ, Vetter CS, Mingari MC, Andersen MH, thor Straten P, Bröcker EB, Becker JC. |
| Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report. J Invest Dermatol. 2002 Apr; 118(4): 595-9. Pubmed | View abstract |
| Guldberg P, Grønbaek K, Worm J, thor Straten P, Zeuthen J. |
| Mutational analysis of oncogenes and tumor suppressor genes in human cancer using denaturing gradient gel electrophoresis. Methods Mol Med. 2002 ; 68(): 125-39. Pubmed | View abstract |
| Knudsen H, Grønbaek K, thor Straten P, Gisselø C, Johansen P, Timshel S, Bergmann OJ, Hansen NE, Ralfkiaer E. |
| A case of lymphoblastoid natural killer (NK)-cell lymphoma: association with the NK-cell receptor complex CD94/NKG2 and TP53 intragenic deletion. Br J Dermatol. 2002 Jan; 146(1): 148-53. Pubmed | View abstract |
| Andersen MH, Keikavoussi P, Bröcker EB, Schuler-Thurner B, Jonassen M, Søndergaard I, Straten PT, Becker JC, Kämpgen E. |
| Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression. Int J Cancer. 2001 Dec; 94(6): 820-4. Pubmed | View abstract |
| Andersen MH, Pedersen LO, Capeller B, Bröcker EB, Becker JC, thor Straten P. |
| Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001 Aug; 61(16): 5964-8. Pubmed | View abstract |
| thor Straten P, Guldberg P, Schrama D, Andersen MH, Moerch U, Seremet T, Siedel C, Reisfeld RA, Becker JC. |
| In situ cytokine therapy: redistribution of clonally expanded T cells. Eur J Immunol. 2001 Jan; 31(1): 250-8. Pubmed | View abstract |
| Schrama D, thor Straten P, Fischer WH, McLellan AD, Bröcker EB, Reisfeld RA, Becker JC. |
| Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity. 2001 Feb; 14(2): 111-21. Pubmed | View abstract |
| Andersen MH, Pedersen LO, Becker JC, Straten PT. |
| Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001 Feb; 61(3): 869-72. Pubmed | View abstract |
| Schrama D, Andersen MH, Terheyden P, Schrøder L, Pedersen LO, thor Straten P, Becker JC. |
| Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients. Cancer Res. 2001 Jan; 61(2): 493-6. Pubmed | View abstract |
| Becker JC, Vetter CS, Schrama D, Bröcker EB, thor Straten P. |
| Differential expression of CD28 and CD94/NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node. Eur J Immunol. 2000 Dec; 30(12): 3699-706. Pubmed | View abstract |
| Sørensen BS, Schmidt H, von der Maase H, Straten PT, Nexø E. |
| Quantification of melanoma cell-specific MART-1 mRNA in peripheral blood by a calibrated competitive reverse transcription-PCR. Clin Chem. 2000 Dec; 46(12): 1923-8. Pubmed | View abstract |
| Moerch U, Schrama D, Guldberg P, Seremet T, Zeuthen J, Becker JC, thor Straten P. |
| Comparative delineation of T cell clonotypes in coexisting syngeneic B16 melanoma. Cancer Immunol Immunother. 2000 Oct; 49(8): 426-32. Pubmed | View abstract |
| Boesen M, Svane IM, Engel AM, Rygaard J, Thomsen AR, Werdelin O. |
| CD8+ T cells are crucial for the ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3-methylcholanthrene. Clin Exp Immunol. 2000 Aug; 121(2): 210-5. Pubmed | View abstract |
| thor Straten P, Kirkin AF, Siim E, Dahlström K, Drzewiecki KT, Seremet T, Zeuthen J, Becker JC, Guldberg P. |
| Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture. Clin Immunol. 2000 Aug; 96(2): 94-9. Pubmed | View abstract |
| Vetter CS, Straten PT, Terheyden P, Zeuthen J, Bröcker EB, Becker JC. |
| Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma. J Invest Dermatol. 2000 May; 114(5): 941-7. Pubmed | View abstract |
| thor Straten P, Guldberg P, Moerch U, Becker JC. |
| Anti-melanocyte T cell responses - methodology versus biology. J Invest Dermatol. 2000 Apr; 114(4): 738-9. Pubmed | View abstract |
| Barfoed AM, Petersen TR, Kirkin AF, Thor Straten P, Claesson MH, Zeuthen J. |
| Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol. 2000 Feb; 51(2): 128-33. Pubmed | View abstract |
| Svane IM, Boesen M, Engel AM. |
| The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice. Med Oncol. 1999 Dec; 16(4): 223-38. Pubmed | View abstract |
| Becker JC, Guldberg P, Zeuthen J, Bröcker EB, Straten PT. |
| Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol. 1999 Dec; 113(6): 1033-8. Pubmed | View abstract |
| thor Straten P, Becker JC, Guldberg P, Zeuthen J. |
| In situ T cells in melanoma. Cancer Immunol Immunother. 1999 Oct; 48(7): 386-95. Pubmed | View abstract |
| Fischer WH, thor Straten P, Terheyden P, Becker JC. |
| Function and dysfunction of CD4(+) T cells in the immune response to melanoma. Cancer Immunol Immunother. 1999 Oct; 48(7): 363-70. Pubmed | View abstract |
| Kirkin AF, thor Straten P, Hansen MR, Barfoed A, Dzhandzhugazyan KN, Zeuthen J. |
| Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones. Cancer Immunol Immunother. 1999 Aug; 48(5): 239-46. Pubmed | View abstract |
| thor Straten P, Guldberg P, Grønbaek K, Hansen MR, Kirkin AF, Seremet T, Zeuthen J, Becker JC. |
| In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol. 1999 Jul; 163(1): 443-7. Pubmed | View abstract |
| Guldberg P, thor Straten P, Ahrenkiel V, Seremet T, Kirkin AF, Zeuthen J. |
| Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene. 1999 Mar; 18(9): 1777-80. Pubmed | View abstract |
| Svane IM, Engel AM, Thomsen NB, Wulf HC, Werdelin O. |
| High MHC class I expression correlates with slow growth in UV-induced skin carcinomas in hairless mice. APMIS. 1998 Nov; 106(11): 1101-7. Pubmed | View abstract |
| Engel AM, Svane IM, Rygaard J, Werdelin O. |
| Immune selection in murine tumors. A study of MCA induced sarcomas in normal and immunodeficient mice. Folia Microbiol (Praha). 1998 ; 43(5): 483-6. Pubmed | View abstract |
| Grønbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K, Guldberg P. |
| Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood. 1998 Nov; 92(9): 3018-24. Pubmed | View abstract |
| thor Straten P, Barfoed A, Seremet T, Saeterdal I, Zeuthen J, Guldberg P. |
| Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE). Biotechniques. 1998 Aug; 25(2): 244-50. Pubmed | View abstract |
| Grønbaek K, Nedergaard T, Andersen MK, thor Straten P, Guldberg P, Møller P, Zeuthen J, Ebbe Hansen N, Hou-Jensen K, Ralfkiaer E. |
| Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. Leukemia. 1998 Aug; 12(8): 1266-71. Pubmed | View abstract |
| Dzhandzhugazyan KN, Kirkin AF, thor Straten P, Zeuthen J. |
| Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Lett. 1998 Jul; 430(3): 227-30. Pubmed | View abstract |
| Straten PT, Guldberg P, Seremet T, Reisfeld RA, Zeuthen J, Becker JC. |
| Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci U S A. 1998 Jul; 95(15): 8785-90. Pubmed | View abstract |
| Guldberg P, Grønbak K, Aggerholm A, Platz A, thor Straten P, Ahrenkiel V, Hokland P, Zeuthen J. |
| Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis. Nucleic Acids Res. 1998 Mar; 26(6): 1548-9. Pubmed | View abstract |
| Thor Straten P, Ralfkiaer E, Hendriks J, Seremet T, Vejlsgaard GL, Zeuthen J. |
| T-cell receptor variable region genes in cutaneous T-cell lymphomas. Br J Dermatol. 1998 Jan; 138(1): 3-12. Pubmed | View abstract |
| Saeterdal I, thor Straten P, Myklebust JH, Kirkin AF, Gjertsen MK, Gaudernack G. |
| Generation and characterization of gp100 peptide-specific NK-T cell clones. Int J Cancer. 1998 Mar; 75(5): 794-803. Pubmed | View abstract |
| Svane IM, Engel AM, Nielsen M, Werdelin O. |
| Interferon-gamma-induced MHC class I expression and defects in Jak/Stat signalling in methylcholanthrene-induced sarcomas. Scand J Immunol. 1997 Oct; 46(4): 379-87. Pubmed | View abstract |
| Guldberg P, Kirkin AF, Gronbaek K, thor Straten P, Ahrenkiel V, Zeuthen J. |
| Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer. 1997 Sep; 72(5): 780-3. Pubmed | View abstract |
| Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. |
| Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res. 1997 Sep; 57(17): 3660-3. Pubmed | View abstract |
| Engel AM, Svane IM, Madsen MW, Pedersen M, Werdelin O. |
| Molecular aberrations in the MHC class I-restricted pathway for antigen presentation in methylcholanthrene sarcomas from nude mice: discrepancies between MHC mRNA and surface protein. Clin Exp Immunol. 1997 Aug; 109(2): 323-31. Pubmed | View abstract |
| Engel AM, Svane IM, Rygaard J, Werdelin O. |
| MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol. 1997 May; 45(5): 463-70. Pubmed | View abstract |
| Thor Straten P, Kirkin AF, Seremet T, Zeuthen J. |
| Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Int J Cancer. 1997 Mar; 70(5): 582-6. Pubmed | View abstract |
| Birck A, thor Straten P, Li L, Hou-Jensen K, Sugár J, Zeuthen J. |
| Analysis of T cell receptor AV and BV chain gene expression by infiltrating lymphocytes in Spitz naevi and in halo naevi. Melanoma Res. 1997 Feb; 7(1): 49-57. Pubmed | View abstract |
| Svane IM, Engel AM, Thomsen AR, Werdelin O. |
| The susceptibility to cytotoxic T lymphocyte mediated lysis of chemically induced sarcomas from immunodeficient and normal mice. Scand J Immunol. 1997 Jan; 45(1): 28-35. Pubmed | View abstract |
| Engel AM, Svane IM, Mouritsen S, Rygaard J, Clausen J, Werdelin O. |
| Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. APMIS. 1996 Sep; 104(9): 629-39. Pubmed | View abstract |
| Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, Werdelin O. |
| Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol. 1996 Aug; 26(8): 1844-50. Pubmed | View abstract |
| thor Straten P, Becker JC, Seremet T, Bröcker EB, Zeuthen J. |
| Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest. 1996 Jul; 98(2): 279-84. Pubmed | View abstract |
| Kirkin AF, thor Straten P, Zeuthen J. |
| Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens. Cancer Immunol Immunother. 1996 May; 42(4): 203-12. Pubmed | View abstract |
| Kirkin AF, Petersen TR, Olsen AC, Li L, thor Straten P, Zeuthen J. |
| Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol Immunother. 1995 Aug; 41(2): 71-81. Pubmed | View abstract |
| Zeuthen J, Birck A, Straten PT. |
| Analysis of T cell receptor alpha beta variability in tumor-infiltrating lymphocytes in primary and metastatic melanoma. Arch Immunol Ther Exp (Warsz). 1995 ; 43(2): 123-33. Pubmed | View abstract |
| Schøller J, thor Straten P, Birck A, Siim E, Dahlström K, Drzewiecki KT, Zeuthen J. |
| Analysis of T cell receptor alpha beta variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions. Cancer Immunol Immunother. 1994 Oct; 39(4): 239-48. Pubmed | View abstract |
| Mouritsen S, Dalum I, Engel AM, Svane IM, Svendsen I, Werdelin O, Elsner H. |
| MHC class II-bound self-peptides can be effectively separated by isoelectric focusing and bind optimally to their MHC class II restriction elements around pH 5.0. Immunology. 1994 Aug; 82(4): 529-34. Pubmed | View abstract |
| Thor Straten P, Schøller J, Hou-Jensen K, Zeuthen J. |
| Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. Int J Cancer. 1994 Apr; 57(1): 138. Pubmed | View abstract |
| Thor Straten P, Schøller J, Hou-Jensen K, Zeuthen J. |
| Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. Int J Cancer. 1994 Jan; 56(1): 78-86. Pubmed | View abstract |
| Petersen BL, Petersen CL, Braendstrup O, Mouritsen S, Engel AM, Svane IM, Werdelin O. |
| Expression of beta 2-microglobulin by premalignant epithelium. APMIS. 1993 Jul; 101(7): 529-36. Pubmed | View abstract |
Center for Cancer Immune Therapy (CCIT) 65Q9 , Department of Hematology, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev
Disclaimer | Top
Disclaimer | Top